Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years of age~* Symptomatic VMA, VMT, or macular hole~* BCVA 20/30 - CF 3' Snellen equivalent~* Willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments~* JETREA® treatment naïve~Exclusion Criteria:~* Patients who are pregnant, planning to become pregnant, or breastfeeding a child~* Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a cup to disc ratio (CDR) \> 0.8 despite treatment with anti-glaucoma medication)~* Active malignancies within the last 12 months except appropriately treated carcinoma in situ of the crevices, melanoma, and prostate cancers treated with a curative intent~* Inability to comply with study or follow-up procedures~* Women who may become pregnant or lactating or intend to become pregnant during the study~* Known drug allergy to ocriplasmin or eplerenone~* Patients with known contraindications Eplerenone as outlined in the package insert

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): Eplerenone
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).